Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.85 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8818548 | 1.00 | ADORA3 (0.85) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8817947 | 0.92 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8820459 | 0.92 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8820007 | 0.91 | ADORA3 (0.83) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8820000 | 0.91 | ADORA3 (0.83) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8819207 | 0.90 | ADORA3 (0.69) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8819192 | 0.90 | ADORA3 (0.69) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8819453 | 0.89 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL8820620 | 0.88 | ADORA3 (0.79) | ADORA3ADORA2AADORA1 | |
| SCHEMBL8820609 | 0.88 | ADORA3 (0.79) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | claimed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | claimed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | claimed |
| WO-1997033590-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | disclosed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |